AzTrials
AzTrials

Schizo Affective DisorderPhase 1NCT03751488

A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

A Phase 1 study testing LY03010 and Invega Sustenna 156 MG in 1 ML Prefilled Syringe in people with Schizo Affective Disorder and Schizophrenia, run by Luye Pharma Group Ltd. at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study will look at the Characteristics of LY03010 Versus INVEGA SUSTENNA® in the blood of Schizophrenia Patients Read more about this study

Who is it for?
Ages 18 to 65 years
What is being tested?
LY03010 and Invega Sustenna 156 MG in 1 ML Prefilled Syringe
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
48 participants
Where
2 sitesUnited States
Study dates
12 Dec 2018to 24 Jul 2019
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Capable of giving informed consent and complying with study procedures;
  • Have an identified support person (e.g., family member, case worker, social worker) considered reliable by the Investigator to help ensure compliance with study visits and to alert staff of any issues of concern;
  • Have a stable place of residence for the 3 months prior to screening and throughout the study;
  • Male or female ≥18 to ≤65 years of age who meets diagnostic criteria for schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-V) for at least 1 year before screening;
  • Be on a stable dose of oral antipsychotic medication(s) other than risperidone, paliperidone, clozapine, ziprasidone, or thioridazine for at least 4 weeks prior to screening;
  • Be clinically stable based on clinical assessments and a Positive and Negative Syndrome Scale (PANSS) total score ≤70 as well as a PANSS HATE (hostility, anxiety, tension and excitement) subtotal score <16 at screening;
Show all 11Show fewer
  • Clinical Global Impression-Severity (CGI-S) score of 1 to 4, inclusive;
  • Body mass index (BMI) ≥17.0 and ≤37 kg/m2; body weight ≥50 kg;
  • Creatinine level within the normal range;
  • All female patients (childbearing potential and non-childbearing potential) must have a negative pregnancy test result at both screening and baseline. Female patients must meet 1 of the following 3 conditions: (i) postmenopausal for at least 12 months without an alternative medical cause, (ii) surgically sterile (hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal occlusion) based on patient report, or (iii) if of childbearing potential (WOCBP), practicing or agree to practice a highly effective contraception method of birth control. Highly effective methods of birth control include an intrauterine device (IUD), intrauterine hormone-releasing system (IUS), and contraceptives (oral, skin patches, or implanted or injectable products) using combined or progestogen-only hormonal contraception associated with inhibition of ovulation. A vasectomized male partner is an acceptable birth control method if the vasectomized partner is the sole sexual partner of the female patient and the vasectomized partner has received medical confirmation of surgical success. Highly effective methods of birth control must be used for at least 14 days prior to study drug dosing, throughout the study, and for another 80 days after the end-of-treatment (EOT) visit (or at least 200 days after the dose, whichever is longer) to minimize the risk of pregnancy;
  • Sexually active fertile male patients must be willing to use acceptable contraception methods (such as double barrier methods of a combination of male condom with either cap, diaphragm or sponge with spermicide) from study drug dosing, throughout the study, and for another 80 days after the EOT visit (or at least 200 days after the dose, whichever is longer) if their partners are women of childbearing potential.

Who cannot join

  • Primary and active DSM-V Axis I diagnosis other than schizophrenia or schizoaffective disorder;
  • Patients who meet DSM-V criteria for substance abuse (moderate or severe) with the exception of caffeine or nicotine in the past 6 months prior to screening, or test positive for a drug of abuse or alcohol at screening or baseline (except positive findings that can be accounted for by documented prescriptions used as prescribed by a treating physician as a part of the treatment for the patient's psychiatric illness);
  • History of treatment resistance, defined as failure to respond to 2 adequate treatment regimens (minimum of 4 weeks at the patient's maximum tolerated dose) of different antipsychotic medications;
  • Known or suspected hypersensitivity or intolerance of risperidone, paliperidone, or any of their excipients (oral risperidone tolerability test will be completed during the screening period, approximately 14 days prior to dosing, for patients without documented evidence [medical record or written statement from a licensed medical practitioner who has treated the patient] of tolerating risperidone or paliperidone, and patients who show an allergic reaction to this test will be excluded from the study);
  • Known non-responders to risperidone or paliperidone;
  • Patients who pose a significant risk of a suicide attempt based on history or the Investigator's judgment; answer "yes" to Suicidal Ideation items 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) for current or past 30 days on the "Baseline/Screening version" at screening; have had suicidal behavior in the last 12 months as measured by the C-SSRS at screening; or are at imminent risk of suicide or violent behavior based on the Investigator's clinical assessment or the C-SSRS assessment of lifetime suicidal ideation or behavior at screening;
Show all 25Show fewer
  • Any one or more of the following 3 conditions: (i) clinically significant liver dysfunction, (ii) hepatitis B surface antigen (HBsAg) positive, or (iii) a serum alanine transaminase (ALT) or aspartate transaminase (AST) > 2x upper limit of normal (ULN) range (if the ALT or AST levels are between 2x and 3x ULN in the first screening test and the elevation may be caused by non-specific reasons in the judgment of the Investigator, a second test can be performed after one week. If the repeated ALT or AST levels are still >2x ULN, the patient must not be included in the study). However, patients who are hepatitis C positive may be enrolled, if this condition is considered stable without treatment and liver function is normal;
  • History of symptomatic orthostatic hypotension with a decrease of ≥20 mmHg in systolic blood pressure (SBP) or decrease of ≥10 mmHg in diastolic blood pressure (DBP) when changing from supine to standing position after having been in the supine position for at least 5 minutes or SBP less than 105 mmHg in a supine position at screening;
  • Uncontrolled diabetes or hemoglobin A1c (HbAlc) level ≥7%, or newly diagnosed within the past 12 months prior to screening;
  • History of neuroleptic malignant syndrome (NMS) or tardive dyskinesia; history of severe akathisia or extra-pyramidal reactions such as dystonia with previous use of risperidone or other neuroleptic treatments; score ≥ 3 on the Global Clinical Assessment of the BARS; or score ≥ 1 on the AIMS at screening. Patients who experience mild extrapyramidal symptoms attributable to study medications will be allowed to continue with appropriate anticholinergic treatment (benztropine, diphenhydramine, and/or trihexyphenidyl);
  • Electroconvulsive therapy within 60 days before screening;
  • Use of a long-acting injectable for the treatment of schizophrenia within 4 weeks (8 weeks for Risperdal Consta®) before screening;
  • Use of injectable paliperidone palmitate within 10 months before screening;
  • Use of clozapine within 4 weeks before screening;
  • Use of nonselective or irreversible monoamine oxidase inhibitor (MAOI) antidepressants within 30 days before screening;
  • Use of other antidepressants unless the patient has been on a stable dose for at least 30 days before screening;
  • Use of strong inducers of either CYP 3A4 or P-glycoprotein (P-gp) within 2 weeks or 5 half-lives, whichever is longer, before screening;
  • QTcF interval greater than 450 msec for males and 470 msec for females or a prior history or presence of circumstances that could increase the risk of torsade de pointes or sudden death in association with the use of drugs that prolong the QTc interval, or other clinically significant ECG findings in the opinion of the Investigator;
  • Clinically significant past medical history (within 2 years) of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, renal, hepatic, bronchopulmonary, neurologic, immunologic disorders, or drug hypersensitivity which, in the judgement of the Investigator, would interfere with the patient's ability to participate in the study;
  • Malignancies with the exception of basal cell or squamous cell skin cancer or in situ cervical cancer within 5 years prior to screening;
  • History or current diagnosis of epilepsy or convulsive disorder other than a single childhood febrile seizure;
  • Participation in a previous clinical study of paliperidone or any other related medications within the past 3 months prior to screening;
  • Receipt of another investigational product within 1 month, or 5 half-lives of the other investigational product, whichever is longer, prior to screening;
  • Donation or blood collection of > 1 unit (approximate 450 mL) of blood (or blood products) or acute loss of blood during the 90 days prior to screening;
  • Any clinical observation or clinical laboratory abnormality including human immunodeficiency virus (HIV) positive test result or abnormal ECG findings at screening or baseline visits which, in the opinion of the Investigator, may endanger the patient or interfere with the endpoints of the study. If the results of clinical laboratory or ECG testing are outside normal reference ranges, the patient may be enrolled but only if these findings are determined not to be clinically significant by the Investigator. This determination must be recorded in the patient's source documents.

Trial locations and contacts

2 sites in 1 country.

United States2 sites

  • Hassman Research Institute

    Berlin, New Jersey, 08009

  • Collaborative Neuroscience Network LLC

    Garden Grove, California, 92845

Other trials in United States

About this study

Official title: A Randomized, Single-Dose, Open-Label, Parallel-Group Study to Determine the Relative Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

This study will look at the Characteristics of LY03010 Versus INVEGA SUSTENNA® in the blood of Schizophrenia Patients

Being tested
LY03010, Invega Sustenna 156 MG in 1 ML Prefilled Syringe
Keywords
Schizophrenia
Medical subject headings
Psychotic Disorders, Schizophrenia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LY03010Drug

    Single Dose of LY03010 at 351 mg or 156 mg or 117mg

  • Invega Sustenna 156 MG in 1 ML Prefilled SyringeDrug

    Single Dose at 156mg

Study groups in NCT03751488
Study groupRoleWhat they receive
LY03010 351mgExperimentalLY03010 at 351 mg
Receives: Drug: LY03010
LY03010 156 mgExperimentalLY03010 at 156 mg
Receives: Drug: LY03010
LY03010 117mgExperimentalLY03010 at 117mg
Receives: Drug: LY03010
INVEGA SUSTENNAActive comparatorINVEGA SUSTENNA 156mg
Receives: Drug: Invega Sustenna 156 MG in 1 ML Prefilled Syringe

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. AUC

    Area under the concentration

    Measured: Time Zero to Last quantifiable concentration (120 days)

  2. CMax

    Maximum observed concentration

    Measured: 120 days

  3. Tmax

    Time to Reach Cmax

    Measured: 120 days

Secondary outcomes (1)

  1. Safety Assessments as measured by Adverse Events that occur during the study

    Safety Assessments as measured by Adverse Events that occur during the study

    Measured: 120 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Nov 2018
  2. Study start12 Dec 2018
  3. Primary completion24 Jul 2019
  4. Study completion24 Jul 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
48 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03751488
Sponsor's protocol ID
LY03010/CT-USA-101
Status last verified
Dec 2018
First submitted
20 Nov 2018
Last updated
13 Aug 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing LY03010 and Invega Sustenna 156 MG in 1 ML Prefilled Syringe in people with Schizo Affective Disorder and Schizophrenia, run by Luye Pharma Group Ltd. at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Aug 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

AUC (time frame: Time Zero to Last quantifiable concentration (120 days)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03751488.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2019; AzTrials last refreshed its copy on 8 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in